Date: 2014-04-04
Type of information: Private placement
Company: Molmed (Italy)
Investors: Fininvest (Italy) Airain Lda (Italy) H-Equity (USA)
Amount: € 4.969 million
Funding type: private placement
Planned used:
Others: * On April 4, 2014, MolMed has announced the conclusion of the share capital increase upon payment - approved by the Extraordinary Shareholders\' Meeting held on 3 March 2014 - with the subscription of the n 277,009 shares corresponding to the n 7,479,243 pre-emptive rights sold at the end of the first offering day on the stock exchange, equal to 3.36% of the newly issued ordinary shares (the \"Shares\") offered, for a total amount of € 166,814.81. Therefore, taking into account the Shares already subscribed on 28 March 2014 within the Offer with preemptive rights, all n. 8,252,092 Shares offered are subscribed for, corresponding to a total amount of € 4,969,409.80. The new share capital of MolMed will therefore amount to €10,874,215.42, divided into n. 231,058,594 ordinary shares with no par value.
Therapeutic area: Cancer - Oncology
